Kaleo Pharmaceuticals, a Richmond, VA-based drug company, announced plans Wednesday to launch the Auvi-Q epinephrine auto-injector into the market again in 2017.
AUVI-Q is a prescription medicine used to treat serious allergic reactions, including anaphylaxis.
Kaleo’s product comes with an in-built voice navigation system to guide users through the injection process.
Kaleo had sold the product to Sanofi but bought it back after Sanofi discontinued the sales after complaints that the device was malfunctioning and not releasing the right dosages of epinephrine.
“After regaining the rights to AUVI-Q, kaléo conducted a thorough manufacturing assessment and invested in new technology and quality systems to ensure accurate, reliable and consistent delivery from the product. AUVI-Q is manufactured on an intelligent, high-tech, 100% automated robotic production line with more than 100 automated quality checks on each AUVI-Q, ensuring a streamlined and consistent production process,” said the company in a statement.
This epinephrine injector will be a viable alternative to Mylan’s EpiPen. Mylan’s EpiPen has been in the news for its high cost. The injector’s cost has gone up by almost $500 in the past few years angering consumers and regulators both. The price rise has even prompted a governmental investigation into the matter.
Earlier in August, Mylan declared that it will soon launch a generic cheaper version of the EpiPen.
Kaleo has refused to divulge the price of its device . But in its statement the company said that ‘Kaléo was aware of the epinephrine auto-injector access and affordability challenges and was working with various stakeholders, including wholesalers, insurance companies, pharmacies and pharmacy benefit managers, to ensure that all patients regardless of insurance coverage, have affordable access to AUVI-Q’.
This means that the list price might be high but the patients will be able to deduct the cost with healthcare benefits and deductibles.